Session information

[WFNMB]

The13th Congress of the World Federation of Nuclear Medicine and Biology(WFNMB2022) » Fukushima Session

Fukushima Session

The progress of development of At-211 targeted alpha particle therapy at Fukushima Medical University and possibilities of combined therapy with external-beam radiation and immunotherapy

Fri. Sep 9, 2022 5:30 PM - 6:30 PM Room1 (Kyoto International Conference Center 1F Main Hall)

Chair：Shunichi Yamashita (Vice president, Fukushima medical university, Fukushima, Japan), Tohru Shiga (Advanced clinical Research Center, Fukushima medical university, Fukushima, Japan)

+Add all to schedule

[WFS-1] The progress of development of At-211 targeted alpha particle therapy at Fukushima Medical University and possibilities of combined therapy with external-beam radiation and immunotherapy

Shunichi Yamashita、Tohru Shiga、Koshin Washiyama、Kazuhiro Takahashi、Yoshiyuki Suzuki (Research Center, Fukushima medical university, Fukushima, Japan)

[WFS-2] Synthesis of At-211 MABG

Kazuhiro Takahashi (Advanced clinical Research Center, Fukushima medical university, Fukushima, Japan)

[WFS-3] Integrated Radiation Therapy including At-211 alpha Nuclear Medicine Therapy

Yoshiyuki Suzuki (Advanced clinical Research Center, Department of Radiation Oncology, Fukushima medical university, Fukushima, Japan)

▲